REQUEST A DEMO
Total
USD $0.00
Search more companies

Pharma Research Bio Co. Ltd. (South Korea)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Pharma Research Bio Co. Ltd. Profile Updated: January 06, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company principally engaged in researching and developing pharmaceuticals. The Company's products mainly consist of BCD600, BCD700 and BCD800, BCD100 humira, BCD200 cosmeceutical and BCD300 lusentis. BCD500 avastin The Company distributes its products within domestic market and to overseas markets including China and the United Kingdom. The Company was founded on October 28, 2009. and its shares are listed on KOREA NEW EXCHANGE(KONEX) on November 05, 2015.

Headquarters
660,Daewangpangyo-Ro, Bundang-Gu
Seongnam; Gyeonggi;

Contact Details: Purchase the Pharma Research Bio Co. Ltd. report to view the information.

Website: http://www.biocnd.com

Basic Information
Total Employees:
Purchase the Pharma Research Bio Co. Ltd. report to view the information.
Outstanding Shares:
Purchase the Pharma Research Bio Co. Ltd. report to view the information.
Financial Auditors:
Purchase the Pharma Research Bio Co. Ltd. report to view the information.
Incorporation Date:
2009
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Company Performance
Financial values in the chart are available after Pharma Research Bio Co. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
60.17%
Total operating revenue
60.27%
Operating profit (EBIT)
152.19%
EBITDA
114.67%
Net Profit (Loss) for the Period
-68.88%
Total assets
8.52%
Total equity
56.52%
Operating Profit Margin (ROS)
11.11%
Net Profit Margin
-47.8%
Return on Equity (ROE)
-27.03%
Debt to Equity Ratio
-29.08%
Quick Ratio
-0.57%
Cash Ratio
-0.11%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?